22 July 2022. This document summarizes current WHO guidance for public health surveillance of coronavirus disease 2019 (COVID-19) in humans caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Reporting period: January 2014 – December 2014
The human immunodeficiency virus (HIV) epidemic in Myanmar is concentrated among men who have sex with men (MSM), people who inject drugs (PWID) and female sex workers (FSW). HIV prevalence in the adult population aged 15 years and older was esti...mated at 0.54% in 2014. But data from HIV Sentinel Sero-Surveillance (HSS) indicates higher prevalence in 2014 among key populations: FSW 6.3%, MSM 6.6% and PWID 23.1%. Compared to 2012 data, the prevalence has declined from 7.1% in FSW and 8.9% in MSM, but has increased from 18% in PWID.
Epidemiological modelling suggests that in 2014 there were around 212,000 people living with HIV (PLHIV) in Myanmar, 34% of whom were females. Nearly 11,000 people died of HIV-related illnesses, compared to approximately 15,000 in 2011. An estimated 9,000 new infections occurred in 2014.
more
The EYE strategy is a comprehensive and long-term strategy built on lessons learned that aims at ending yellow fever epidemics by 2026, and consists of three strategic objectives:
protect at-risk populations;
prevent international spread; and
contain outbreaks rapidly.
Accessed 15th of October 2015
Assessment in action series
Key Findings from Azerbaijan, Georgia, Kyrgyzstan, Russia, and Ukraine
Writing by Katya Burns
Editing by Paul Silva and Roxanne Saucier
In this edition, the Antimicrobial Resistance chapter discusses the growing, dangerous trend of antimicrobial resistance and the potential catastrophic consequences on global health.
Chapter 1 of Frontier 2017: Emerging Issues of Environmental Concern
Annex 5, WHO Technical Report Series 1010, 2018
Health Evidence Network synthesis report 53
Pharmaceutical regulators are at the forefront of ensuring that only safe and effective medicines are authorized and available in the market. This document builds on the recommendations in the above publication and has been prepared to specifically assist national medicines regulatory authorities to... understand the nature and extent of oxytocin quality issues and to provide key technical information and quality requirements for oxytocin products in dossier assessments. Furthermore, this document also presents recommendations on other regulatory actions needed to ensure that only quality-assured oxytocin products are authorized and made available to women.
more